Literature DB >> 26787377

Bacteremic Pneumonia before and after Withdrawal of 13-Valent Pneumococcal Conjugate Vaccine from a Public Vaccination Program in Spain: A Case-Control Study.

Alfredo Tagarro1, Andrea Benito2, Aida Sánchez3, Esteban Aznar3, Enrique Otheo4, David Sanz-Rosa5.   

Abstract

OBJECTIVE: To compare the incidence and epidemiology of bacteremic community-acquired pneumonia (CAP) in the setting of changes in 13-valent pneumococcal conjugate vaccine (PCV13) coverage. STUDY
DESIGN: In the region of Madrid, universal immunization with the PCV13 started in May 2010. In July 2012, public funding ceased. Vaccination coverage decreased from >95% to 82% in 2013 and to 67% in 2014. We performed a multicenter surveillance and case-control study from 2009-2014. Cases were hospitalized children with bacteremic CAP. Controls were children selected 1:1 from next-admitted with negative blood cultures and typical, presumed bacterial CAP.
RESULTS: Annual incidence of bacteremic CAP declined from 7.9/100,000 children (95% CI 5.1-11.1) in 2009 to 2.1/100,000 children (95% CI 1.1-4.1) in 2012. In 2014, 2 years after PCV13 was withdrawn from the universal vaccination program, the incidence of bacteremic CAP increased to 5.4/100,000 children (95% CI 3.5-8.4). We enrolled 113 cases and 113 controls. Streptococcus pneumoniae caused most of bloodstream infections (78%). Empyema was associated with bacteremia (P = .003, OR 3.6; 95% CI 1.4-8.9). Simple parapneumonic effusion was not associated with bacteremia. Incomplete PCV immunization was not a risk factor for bacteremic pneumonia.
CONCLUSIONS: High rate of PCV13 immunization was associated with decreased incidence of bacteremic CAP; this incidence increased when rate of immunization fell. Empyema (but not parapneumonic pleural effusion) was associated with bacteremia.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26787377     DOI: 10.1016/j.jpeds.2015.12.031

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  5 in total

1.  Patterns and trends of pediatric bloodstream infections: a 7-year surveillance study.

Authors:  N Buetti; A Atkinson; L Kottanattu; J Bielicki; J Marschall; A Kronenberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-11-24       Impact factor: 3.267

Review 2.  A reflection on invasive pneumococcal disease and pneumococcal conjugate vaccination coverage in children in Southern Europe (2009-2016).

Authors:  Marta Moreira; Olga Castro; Melissa Palmieri; Sofia Efklidou; Stefano Castagna; Bernard Hoet
Journal:  Hum Vaccin Immunother       Date:  2016-12-20       Impact factor: 3.452

3.  Bacteremic Community-Acquired Pneumonia in Ethiopian Children: Etiology, Antibiotic Resistance, Risk Factors, and Clinical Outcome.

Authors:  Abel Abera Negash; Daniel Asrat; Workeabeba Abebe; Tewodros Hailemariam; Tsegaye Hailu; Abraham Aseffa; Mario Vaneechoutte
Journal:  Open Forum Infect Dis       Date:  2019-01-23       Impact factor: 3.835

4.  Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis.

Authors:  Sarah Pugh; Matt Wasserman; Margaret Moffatt; Susana Marques; Juan Manuel Reyes; Victor A Prieto; Davy Reijnders; Mark H Rozenbaum; Juha Laine; Heidi Åhman; Raymond Farkouh
Journal:  Infect Dis Ther       Date:  2020-02-24

5.  Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada.

Authors:  Michele Wilson; Matt Wasserman; Taj Jadavi; Maarten Postma; Marie-Claude Breton; Francois Peloquin; Stephanie Earnshaw; Cheryl McDade; Heather Sings; Raymond Farkouh
Journal:  Infect Dis Ther       Date:  2018-06-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.